Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis (SIMPL)

This study has been withdrawn prior to enrollment.
(Local pharmacy unwilling to comply with study protocol)
Sponsor:
Information provided by:
Cambridge University Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT00539799
First received: October 4, 2007
Last updated: May 28, 2008
Last verified: May 2008

October 4, 2007
May 28, 2008
Not Provided
Not Provided
Feasibility (recruitment rate and protocol adherence) [ Time Frame: 12 months ]
Same as current
Complete list of historical versions of study NCT00539799 on ClinicalTrials.gov Archive Site
1) time to major renal and non-renal relapses of SLE 2) time to minor relapses of SLE 3) health related quality of life 4) adverse events/side-effects 5) accrual of SLE related organ damage 6) renal function [ Time Frame: 24 months ]
Same as current
Not Provided
Not Provided
 
Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis
Corticosteroids in the Maintenance Therapy of Proliferative Lupus Nephritis: a Randomized Pilot Study

There is debate as to whether long-term low-dose steroids such as prednisolone help to suppress relapses of systemic lupus erythematosus (SLE) in patients who are in remission from their lupus nephritis. If low-dose prednisolone reduces relapses, these beneficial effects may be counter-balanced by the long-term side-effects associated with prednisolone. This pilot study will determine the feasibility of conducting a larger randomized control trial that will answer the question of whether or not long-term low-dose prednisolone (5 - 7.5 mg/day) reduces the flares of SLE in patients with previous lupus nephritis.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Lupus Nephritis
  • Drug: prednisolone
    5 - 7.5 mg/day
  • Drug: Placebo
    Matched placebo to prednisolone
  • Active Comparator: 1
    Long-term low-dose prednisolone (5 - 7.5 mg/day)
    Intervention: Drug: prednisolone
  • Placebo Comparator: 2
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
15
Not Provided
Not Provided

Inclusion Criteria:

  • age at least 18 years
  • diagnosis of SLE by ACR criteria
  • diagnosis of proliferative lupus nephritis (ISN/RPS class III or IV)
  • currently on prednisolone (5 to 20 mg/day)
  • in partial or complete remission for at least 3 months

Exclusion Criteria:

  • currently pregnant
  • in end-stage renal failure
  • receiving corticosteroids for an indication other than lupus nephritis
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00539799
A091040, EUDRACT: 2007-003923-20
Yes
Not Provided
Cambridge University Hospitals NHS Foundation Trust
Not Provided
Principal Investigator: David Jayne, MD Cambridge University Hospitals NHS Foundation Trust
Principal Investigator: Michael Walsh, MD Cambridge University Hospitals NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP